Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Inventory (2018 - 2026)

Akebia Therapeutics has reported Inventory over the past 8 years, most recently at $15.6 million for Q4 2025.

  • Quarterly Inventory fell 3.9% to $15.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.6 million through Dec 2025, down 3.9% year-over-year, with the annual reading at $15.6 million for FY2025, 3.9% down from the prior year.
  • Inventory was $15.6 million for Q4 2025 at Akebia Therapeutics, down from $18.6 million in the prior quarter.
  • Over five years, Inventory peaked at $45.2 million in Q3 2022 and troughed at $15.6 million in Q4 2025.
  • The 5-year median for Inventory is $21.2 million (2022), against an average of $26.7 million.
  • Year-over-year, Inventory plummeted 63.77% in 2021 and then surged 34.3% in 2022.
  • A 5-year view of Inventory shows it stood at $36.6 million in 2021, then plummeted by 41.12% to $21.6 million in 2022, then decreased by 27.25% to $15.7 million in 2023, then grew by 3.52% to $16.2 million in 2024, then fell by 3.9% to $15.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Inventory are $15.6 million (Q4 2025), $18.6 million (Q3 2025), and $16.7 million (Q2 2025).